Skip to content
Bored Studies
RecruitingAccepts healthy volunteersEarly Phase 1

Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes

Anna Stanhewicz, PhD · NCT05917587

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–45 · Women only
Healthy volunteers
Accepted
Study type
Interventional · Early Phase 1
Target enrollment
30
US sites recruiting
1
Study start
September 11, 2024
Record last updated
May 13, 2025

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this investigation is to examine the mechanisms mediating vascular dysfunction in women who have had gestational diabetes and how metformin may be a valuable treatment tool to improve microvascular function in these women before the onset of disease.

Being studied: Metformin Hydrochloride; placebo

Conditions: Gestational Diabetes

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • ≥12 weeks and ≤5 years postpartum
  • history of GDM or healthy pregnancy

Exclusion Criteria

  • prediabetes or diabetes (HbA1c ≥5.7%)
  • current tobacco use
  • cardiovascular or metabolic disease
  • cardiovascular or metabolic medication
  • history of hypertension during pregnancy
  • current pregnancy

Recruiting US locations

  • University of Iowa

    Iowa City, IA 52242

    Site contact: Anna Stanhewicz, PhD · 319-467-1732 · anna-stanhewicz@uiowa.edu

Study contacts (from the official record)

  • Anna Stanhewicz, PhD · 3194671732 · anna-stanhewicz@uiowa.edu
All diabetes studies in Iowa →
Metformin for the Treatment of Microvascular Dysfunction After… (NCT05917587) | Bored Studies